Showing 1 - 20 results of 37,424 for search '(((( base small decrease ) OR ( _ ((point decrease) OR (_ decrease)) ))) OR ( a larger decrease ))', query time: 0.54s Refine Results
  1. 1

    Guidelines and policy changes for different alert levels in Gauteng. The time intervals are separated by points of inflection identified in Edholm <i>et al</i>. [10]; these points separate time periods where the rate of cumulative cases was increasing from periods when the rate of cumulative cases was decreasing [10], Fig 1].... by Folashade B. Agusto (3663010)

    Published 2025
    “…[<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0325619#pone.0325619.ref010" target="_blank">10</a>]; these points separate time periods where the rate of cumulative cases was increasing from periods when the rate of cumulative cases was decreasing [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0325619#pone.0325619.ref010" target="_blank">10</a>], Fig 1]. …”
  2. 2

    Content analysis of groups with decreased confidence. by Yasutaka Yanagita (11105508)

    Published 2025
    “…<p>Content analysis of groups with decreased confidence.</p>…”
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8

    The introduction of mutualisms into assembled communities increases their connectance and complexity while decreasing their richness. by Gui Araujo (22170819)

    Published 2025
    “…(C) Mutualism also promotes an increase in network connectance when introduced into assembled communities, while stopping mutualistic interactions from entering an assembled system slowly decreases it. (D) As a result, the introduction of mutualistic interactions promotes a growth in complexity in communities where it was once established as low, while stopping the introduction of further mutualistic interactions causes a slight decrease in complexity. …”
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17

    Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

    Published 2025
    “…The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
  18. 18
  19. 19
  20. 20